PRNewswire (Wed, 24-Apr 7:05 AM ET)
Edgewise gets EU orphan drug status for muscular dystrophy drug
Seeking Alpha News (Tue, 23-Apr 10:29 AM ET)
PRNewswire (Thu, 28-Mar 7:05 AM ET)
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PRNewswire (Wed, 27-Mar 4:05 PM ET)
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewswire (Mon, 11-Mar 7:05 AM ET)
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
PRNewswire (Wed, 6-Mar 11:21 PM ET)
REGENXBIO Announces Proposed Public Offering of Common Stock
PRNewswire (Wed, 6-Mar 4:10 PM ET)
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL
PRNewswire (Tue, 5-Mar 7:05 AM ET)
PRNewswire (Thu, 29-Feb 4:57 PM ET)
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Regenxbio trades on the NASDAQ stock market under the symbol RGNX.
As of April 26, 2024, RGNX stock price climbed to $16.33 with 131,642 million shares trading.
RGNX has a beta of 1.73, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.14 to the broad based SPY ETF.
RGNX has a market cap of $800.87 million. This is considered a Small Cap stock.
Last quarter Regenxbio reported $22 million in Revenue and -$1.43 earnings per share. This fell short of revenue expectation by $-12 million and missed earnings estimates by -$.16.
In the last 3 years, RGNX stock traded as high as $46.46 and as low as $11.83.
The top ETF exchange traded funds that RGNX belongs to (by Net Assets): IJR, VTI, VB, XBI, IWM.
RGNX has underperformed the market in the last year with a price return of -13.7% while the SPY ETF gained +26.9%. However, in the short term, RGNX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.2% vs +4.6% return in SPY. But in the last 2 weeks, RGNX shares have been beat by the market, returning -14.1% compared to an SPY return of -1.8%.
RGNX support price is $15.39 and resistance is $16.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX stock will trade within this expected range on the day.